News

HDA UK Media And Political Bulletin – 16 January 2017

Media Summary

Exiting the EU Committee report: ABPI response

ABPI, 14 January 2017

The Association of the British Pharmaceutical Industry (ABPI) has published its response to the Exiting the EU Select Committee report. The ABPI argues that alignment with EU medicines regulation is key and the UK should look to maintain as much harmonisation of medicine regulation as possible. The ABPI supports the focus on transitional arrangements and the UK’s future partnerships with European regulatory agencies and bodies.

January 2017 Price Concessions

Pharmaceutical Services Negotiating Committee, 13 January 2017 

The Department of Health have granted the following price concessions for January 2017:

Drug

Pack size

Price concession

Amitriptyline 50mg tablets

28

£3.40

Buspirone 5mg tablets

30

£19.54

Candesartan 2mg tablets

7

£2.25

Dapsone 50mg tablets

28

£46.19

Exemestane 25mg tablets

30

£9.60

Flecainide 100mg tablets

60

£13.50

Flecainide 50mg tablets

60

£11.25

Lorazepam 1mg tablets

28

£6.05

Mirtazapine 15mg tablets

28

£5.95

Mirtazapine 30mg tablets

28

£1.61

Mirtazapine 45mg tablets

28

£5.95

Naratriptan 2.5mg tablets

6

£24.55

Nitrofurantoin 100mg tablets

28

£14.50

Nitrofurantoin 50mg tablets

28

£17.50

Quinagolide 75microgram tablets

30

£64.97

Ropinirole 0.5mg tablets

28

£16.32

Ropinirole 1mg tablets

84

£56.71

Ropinirole 5mg tablets

84

£165.00

Valsartan 160mg capsules

28

£5.20

Valsartan 40mg capsules

28

£4.72

Valsartan 80mg capsules

28

£5.55

Zolmitriptan 2.5mg tablets

6

£15.30

No endorsements are required as these prices will automatically be applied to this month’s prescriptions.

When any NCSO or price concession announcements are made, these appear on the Generic Shortages page (psnc.org.uk/ncso) and are emailed to those subscribed to this mailing list.

Parliamentary Coverage

There is no parliamentary coverage.

Full Coverage

Exiting the EU Committee report: ABPI response

ABPI, 14 January 2017

The Association of the British Pharmaceutical Industry (ABPI) has responded to today’s publication of the Exiting the EU Committee report into the process for exiting the European Union and the Government’s negotiating objectives.

​​​In December, Dr Virginia Acha, ABPI Executive Director – Research, Medical & Innovation gave evidence to the Exiting the EU Committee stating that a primary objective for Government in Brexit negotiations should be to secure alignment and cooperation with EU medicines regulation.

​The UK is currently part of the European Medicines Agency (EMA), a network that facilitates the harmonisation of medicines regulation for more than 25% of global pharmaceutical market and over 500m patients. This includes EU member states, and non-EU members of the European Economic Area (EEA), Iceland, Liechtenstein and Norway.

Robust and internationally aligned medicines regulation, has been essential for protecting and improving the health of patients, has ensured effectiveness and safety, and has brought forward advances in medical innovation to large patient populations in a way that minimises delays and cost.

The UK having an aligned framework in place for medicines regulation ‘from day one’ of leaving the EU would be important for maintaining drugs availability and supply.

Upon reviewing the Committee’s report published today​, the ABPI welcomes their explicit focus on the importance of transitional arrangements and the UK’s future relationships with regulatory agencies and bodies.

Mike Thompson, ABPI, Chief Executive ​commented:

“We welcome the Committee’s focus on the importance of getting medicine regulation right from day one of the UK leaving the European Union.

Securing continued regulatory cooperation and alignment with the EU for medicines will be in the best interests of the UK Government, EU member states and patients.

HDA UK Media And Political Bulletin – 16 January 2017

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?